Breaking News Instant updates and real-time market news.

TXMD

TherapeuticsMD

$5.63

0.06 (1.08%)

08:00
07/17/17
07/17
08:00
07/17/17
08:00

TherapeuticsMD drops as TX-004HR update seen not reading 'well at all'

Shares of TherapeuticsMD (TXMD), a women's healthcare company, plunged in pre-market trading after the company provided a regulatory update on the status of its New Drug Application for TX-004HR. REGULATORY UPDATE: In a statement, TherapeuticsMD provided an update on the status of its NDA for TX-004HR, its investigational applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse, saying that it participated in a Type A Post-Action Meeting on June 14 with the FDA's Division of Bone, Reproductive, and Urologic Products. At the meeting, the two sides discussed the complete response letter that TherapeuticsMD previously received for the NDA, which also allowed the company to present new information it believes could address concerns raised in the letter and "positively" impact the status of the NDA. TherapeuticsMD said it has formally submitted the new information for consideration per the FDA's request. However, the company noted that while it continues to have "productive" dialogue with the FDA related to its review, it has not yet received a formal timeline for a conclusion of this review. TherapeuticsMD said it "looks forward" to working with the FDA to address its concerns and sees further clarity on the pathway forward for the NDA "in the coming weeks," adding that it "reserves the right to pursue the FDA's formal dispute resolution process if a reasonable timeline to address such concerns cannot be established." WHAT'S NOTABLE: On May 8, TherapeuticsMD said it received the CRL from the FDA regarding the TX-004HR NDA. At the time, the company said it planned to meet with the FDA as soon as possible to address the concerns raised in the letter, which involved "the lack of long-term endometrial safety data for TX-004HR beyond the 12-weeks studied in the pivotal phase 3 Rejoice Trial." Adam Feuerstein, who previously wrote about biotech stocks for TheStreet and currently is a senior writer for StatNews, tweeted in May that the company lacks the cash to conduct the type of safety study of TX-004HR requested by the FDA, without cutting expenses or raising more money, adding that a delay for this product "could be fatal" for the company. This morning, Feuerstein tweeted that TherapeuticsMD's regulatory update on resolving the CRL "does not read well at all." ANALYST COMMENTARY PRIOR TO UPDATE: Oppenheimer analyst Jay Olson upgraded TherapeuticsMD to Outperform recently ahead of the FDA meeting update, and said there was a "reasonable probability" of positive news. Olson argued that data on complete response letters provides confidence that there are likely no other TX-004HR approvability issues besides lack of long-term endometrial safety data beyond the 12 weeks studied in REJOICE and that there are likely no approvability issues that would have any implications for TX-001HR. PRICE ACTION: In pre-market trading, TherapeuticsMD is down 12%.

TXMD TherapeuticsMD
$5.63

0.06 (1.08%)

06/13/17
JEFF
06/13/17
NO CHANGE
JEFF
TherapeuticsMD could use data to push post-approval study, says Jefferies
Jefferies analyst Matthew Andrews says that TherapeuticsMD could use prior data - including a finding that low-dose vaginal estrogen is safe for women with breast cancer and a finding that estrogen delivered in a patch is safe for two years - to convince an FDA panel to allow the company to address concerns raised in a complete response letter for its TX-004 drug with a post-approval study instead of a pre-approval study. Andrews keeps a $15 price target and a buy rating on the shares.
05/23/17
STFL
05/23/17
NO CHANGE
Target $20
STFL
Buy
TherapeuticsMD scheduled to meet FDA on June 14, says Stifel
Stifel analyst Annabel Samimy says TherapeuticsMD's Type A meeting with the FDA to discuss last month's Complete Response Letter is scheduled for June 14. The analyst sees two likely scenarios from the meeting. The first has TherapeuticsMD seeking class labeling with a Phase 4 post-marketing study to eventually amend the label. And the second has the company seeking an appeal should FDA hold firm in the 12-month safety requirement to justify a differentiated label. Samimy is "convinced" that TX-004HR remains approvable and she keeps a Buy rating on the shares with a $20 price target.
05/09/17
JEFF
05/09/17
NO CHANGE
Target $15
JEFF
Buy
TherapeuticsMD price target lowered to $15 from $18 at Jefferies
Jefferies analyst Matthew Andrews lowered his price target for TherapeuticsMD to $15 citing a lower probability of success for TX-004HR following the Complete Response Letter. The analyst, with a 55% probability of approval now, believes the FDA's endometrial safety concerns appear addressable. If FDA agrees to approve '004 with a post-approval study, it could obtain a class label with boxed warning, Andrews tells investors in a research note. He keeps a Buy rating on TherapeuticsMD.
05/09/17
OPCO
05/09/17
DOWNGRADE
OPCO
Perform
TherapeuticsMD downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Jay Olson downgraded TherapeuticsMD to Perform saying he's surprised by the FDA's request for long-term safety data. The analyst prefers to move to the sidelines amid uncertainty resulting from the Complete Response Letter.

TODAY'S FREE FLY STORIES

HOG

Harley-Davidson

$49.96

1.32 (2.71%)

12:30
07/27/17
07/27
12:30
07/27/17
12:30
Options
Heavy call activity in Harley Davidson as shares rally »

Heavy call activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

12:30
07/27/17
07/27
12:30
07/27/17
12:30
General news
Atlanta Fed's final Q2 GDPNow estimate was boosted to 2.8% »

Atlanta Fed's final…

VBIV

VBI Vaccines

$4.61

-0.03 (-0.65%)

12:25
07/27/17
07/27
12:25
07/27/17
12:25
Conference/Events
VBI Vaccines to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 26

    Sep

DAL

Delta Air Lines

$50.74

-0.395 (-0.77%)

, AFLYY

Air France-KLM

$14.14

0.18 (1.29%)

12:22
07/27/17
07/27
12:22
07/27/17
12:22
Hot Stocks
Delta Air Lines to acquire 10% equity stake in Air France-KLM for EUR375M »

Delta Air Lines (DAL)…

DAL

Delta Air Lines

$50.74

-0.395 (-0.77%)

AFLYY

Air France-KLM

$14.14

0.18 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GG

Goldcorp

$12.88

-0.91 (-6.60%)

12:20
07/27/17
07/27
12:20
07/27/17
12:20
Options
Repeat activity in GoldCorp after earnings »

Repeat activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

12:20
07/27/17
07/27
12:20
07/27/17
12:20
General news
Treasury Option Action: heavy put activity »

Treasury Option Action:…

$NSD

NASDAQ Market Internals

12:17
07/27/17
07/27
12:17
07/27/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
07/27/17
07/27
12:16
07/27/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$78.91

-0.4533 (-0.57%)

12:15
07/27/17
07/27
12:15
07/27/17
12:15
Options
Wayfair put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

TDOC

Teladoc

$31.78

-2.575 (-7.50%)

, AMZN

Amazon.com

$1,052.80

12.93 (1.24%)

12:11
07/27/17
07/27
12:11
07/27/17
12:11
Recommendations
Teladoc, Amazon.com analyst commentary  »

Teladoc selloff on Amazon…

TDOC

Teladoc

$31.78

-2.575 (-7.50%)

AMZN

Amazon.com

$1,052.80

12.93 (1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 02

    Aug

  • 16

    Aug

  • 18

    Aug

SBUX

Starbucks

$57.94

-0.61 (-1.04%)

12:11
07/27/17
07/27
12:11
07/27/17
12:11
Technical Analysis
Technical Earnings Preview: Starbucks in consolidation phase before news »

The stock has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 23

    Aug

AAPL

Apple

$153.46

0.72 (0.47%)

12:06
07/27/17
07/27
12:06
07/27/17
12:06
Periodicals
Breaking Periodicals news story on Apple »

Apple to discontinue iPod…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

NTES

NetEase

$312.15

3.26 (1.06%)

12:05
07/27/17
07/27
12:05
07/27/17
12:05
Options
NetEase call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

WABC

Westamerica

$54.57

-1.82 (-3.23%)

12:04
07/27/17
07/27
12:04
07/27/17
12:04
Hot Stocks
Westamerica announces announces stock repurchase plan »

Westamerica…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:00
07/27/17
07/27
12:00
07/27/17
12:00
General news
Treasury's $20 B 14-day cash management bill saw pretty good demand »

Treasury's $20 B…

INTC

Intel

$34.75

0.08 (0.23%)

12:00
07/27/17
07/27
12:00
07/27/17
12:00
Periodicals
Intel sells four offices buildings, development center in Alameda, SVBJ says »

Intel has sold four…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 10

    Aug

  • 15

    Aug

  • 28

    Aug

HOG

Harley-Davidson

$49.03

0.39 (0.80%)

, TSLA

Tesla

$343.85

4.25 (1.25%)

11:58
07/27/17
07/27
11:58
07/27/17
11:58
Hot Stocks
Harley-Davidson jumps amid chatter of Tesla partnership »

The move higher in shares…

HOG

Harley-Davidson

$49.03

0.39 (0.80%)

TSLA

Tesla

$343.85

4.25 (1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 08

    Aug

  • 02

    Oct

RYAM

Rayonier Advanced Materials

$15.72

-0.11 (-0.69%)

11:56
07/27/17
07/27
11:56
07/27/17
11:56
Hot Stocks
Tembec shareholders approve deal with Rayonier Advanced Materials »

Rayonier Advanced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 07

    Aug

TKC

Turkcell

$9.29

0.29 (3.22%)

11:55
07/27/17
07/27
11:55
07/27/17
11:55
Hot Stocks
Breaking Hot Stocks news story on Turkcell 

Turkcell trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOSL

Fossil

$10.83

-0.19 (-1.72%)

11:55
07/27/17
07/27
11:55
07/27/17
11:55
Hot Stocks
Breaking Hot Stocks news story on Fossil »

Classic Fund Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$52.06

0.5 (0.97%)

11:55
07/27/17
07/27
11:55
07/27/17
11:55
Options
CSX put volume heavy and directionally bearish »

Bearish flow noted in CSX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

EXPE

Expedia

$156.94

2.37 (1.53%)

11:54
07/27/17
07/27
11:54
07/27/17
11:54
Periodicals
Expedia investing $350M in online travel portal Traveloka, The Information says »

Expedia is said to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

NVDA

Nvidia

$167.26

1.91 (1.16%)

, TSLA

Tesla

$343.85

4.25 (1.25%)

11:54
07/27/17
07/27
11:54
07/27/17
11:54
Periodicals
House panel supports speeding self-driving car development, Reuters says »

A House panel voted 54-0…

NVDA

Nvidia

$167.26

1.91 (1.16%)

TSLA

Tesla

$343.85

4.25 (1.25%)

GOOG

Alphabet

$947.80

-2.9 (-0.31%)

GOOGL

Alphabet Class A

$965.31

-3.72 (-0.38%)

INTC

Intel

$34.75

0.08 (0.23%)

AAPL

Apple

$153.46

0.72 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 01

    Aug

  • 02

    Aug

  • 08

    Aug

  • 10

    Aug

  • 15

    Aug

  • 16

    Aug

  • 18

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Oct

CA

CA Technologies

$34.65

-0.38 (-1.08%)

11:53
07/27/17
07/27
11:53
07/27/17
11:53
Periodicals
CA Technologies, BMC Software merger talks end, WSJ reports »

Merger talks between CA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 09

    Aug

IP

International Paper

$57.37

0.975 (1.73%)

11:52
07/27/17
07/27
11:52
07/27/17
11:52
Technical Analysis
Technical View: International Paper near highs of the day »

The shares are up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.